UNSPSC 51201627: Haemophilus B vaccine

This classification denotes a vaccine for a species of haemophilus found on the mucous membranes of humans and a variety of animals, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier LUY6P8763W. The US Centers for Disease Control recognizes this preparation under Concept Code 51 and CDC Code System OID 2.16.840.1.113883.12.292.

UNSPSC 51201627 Haemophilus B vaccine is a Commodity code that nominally covers Haemophilus influenzae type B immunizations, though the recent state and local activity under this code does not match its scope. The single identified recent opportunity is a sole source procurement notice from the Mississippi State Department of Health for Yellow Fever Vaccine from Sanofi Pasteur, Inc., posted July 13, 2026. This represents a mismatch: the code name specifies Haemophilus B vaccine, but the actual solicitation is for an unrelated vaccine product. State and local health departments, including state departments of health, are the primary issuing bodies procuring under this code when activity does occur, though the sourcing may be restricted or sole source when a particular vaccine formulation or manufacturer is clinically required or exclusively available.

The code shows minimal recent activity in state and local procurement. The sole identified opportunity is from Mississippi, with objections to the sole source designation due August 3, 2026 at 10:00 a.m. CST. No response or award value is specified in the notice. The mismatch between the code's nominal commodity (Haemophilus B vaccine) and the actual solicitation (Yellow Fever Vaccine) suggests either a tagging error in the opportunity database or a code that poorly reflects current procurement patterns in this category. Firms tracking vaccine supply contracts should verify the actual vaccine type and manufacturer requirements in each solicitation rather than relying on UNSPSC categorization alone.